miR-17 在结肠癌中的表达及其临床意义

目的探讨miR-17在结肠癌中的表达与临床病理特征间的关系。方法选取2012年1月至2013年6月经手术切除的50例原发性结肠癌及癌旁组织标本,采用实时荧光定量PCR分析miR-17的表达情况。结果相对于癌旁组织,50例结肠癌组织中miR-17表达下调(P<0.05),其表达与TNM分期以及浸润深度有关(均P<0.05)。结论 miR-17参与了结肠癌的发生发展。     

血浆miR-92a与骨肉瘤预后相关性研究

背景与目的：骨肉瘤是儿童和年轻成人最常见的原发性恶性骨肿瘤,目前尚无高特异度、高灵敏度的预后预测指标。该研究旨在探讨血浆miR-92a表达水平与骨肉瘤临床病理及预后的关系。方法：收集30例健康体检者和45例骨肉瘤患者术前及术后血浆,通过实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,RTFQ-PCR)检测血浆miR-92a水平。以术前miR-92a≥5为界限,将骨肉瘤患者分为高表达组和低表达组。结果：骨肉瘤患者血浆miR-92a水平显著高于正常体检人群,患者术前miR-92a水平远高于术后。患者术前miR-92a表达水平与患者的性别、年龄、肿瘤部位、肿瘤大小和组织学类型等无关,而与Enneking分期、肿瘤坏死率和肺转移相关。Kaplan-Meier分析高表达miR-92a的骨肉瘤预后差(P=0.035)。结论：骨肉瘤患者血浆miR-92a表达水平与生存率相关,可能是骨肉瘤一项有价值的预后指标。     

miR-21的功能分析及其在结肠癌中的临床意义

目的:分析miR-21的功能及其在结肠癌中的临床意义。方法:采用miRWalk在线工具预测和筛选miR-21的靶基因,并使用DAVID分析靶基因的功能和信号通路;检测结肠癌患者和健康对照人群血清以及癌组织和癌旁组织标本的miR-21的表达水平;使用TCGA数据库中结肠癌的数据,分析miR-21表达水平与临床病理参数的关系以及与患者预后的关系。结果:共筛选出429个miR-21的靶基因,靶基因功能分析提示这些基因主要参与了正性调节代谢过程、蛋白结合等。结肠癌患者血清miR-21表达水平显著高于健康对照人群,差异有统计学意义（P<0.05）。TCGA数据显示,结肠癌组织中的miR-21表达水平与肿瘤的临床分期、肿瘤侵袭程度、淋巴结转移分期、远处转移分期无显著差异（P>0.05）。生存分析显示组织中高表达miR-21的患者其生存时间较低表达者短（P<0.05）。结论:miR-21调控多个肿瘤发生相关的基因,在结肠癌发生过程中具有重要的调控作用。结肠癌患者miR-21表达水平显著高于健康人群,且miR-21高表达的患者预后差。     

血浆miR-221在小细胞肺癌患者血浆中的表达及其临床意义

背景与目的：MicroRNAs(miRNAs,miR)与肿瘤的发生、发展和转移密切相关。肿瘤组织中miRNAs表达水平的变化可能会引起循环miRNAs随之改变。本研究目的是探讨小细胞肺癌(small cell lungcancer,SCLC)患者临床标本中miR-221的表达及其临床意义。分析miR-221在51例SCLC患者及20例健康对照者血浆和组织中的表达及其与各临床病理参数的关系。方法：采用实时荧光定量PCR法检测51例SCLC患者癌组织、癌旁及正常组织中miR-221的表达。进一步检测血浆miR-221在51例SCLC患者及20例健康对照者中的表达。结合临床资料分析其表达在临床中的作用和意义,判定血浆miR-221能否作为SCLC早期诊断、治疗及预后的标志。结果：miR-221在SCLC组织中的表达水平较癌旁及正常肺组织高;血浆miR-221在SCLC患者中的表达较健康对照者高(P＜0.05)。miR-221的表达与患者的性别、年龄无关(P＞0.05),与疾病分期、对化疗的敏感性及生存期密切相关,差异具有统计学意义(P＜0.05)。Cox回归分析发现疾病分期、miR-221的表达可作为独立的预后因子。结论：血浆miR-221的表达与SCLC的肿瘤分期、对化疗的敏感性和生存期相关。检测血浆miR-221可作为评估SCLC患者临床预后的靶基因。     

miR-214在胃癌患者外周血中的表达及其临床意义

目的探讨miR-214在胃癌中的表达及临床意义。方法采用实时荧光定量PCR法,检测40例胃癌患者癌组织及癌旁组织中miR-214的差异表达;同时检测血浆miR-214在56例胃癌患者及40例正常组织中的表达。结果miR-214在胃癌组织中的表达水平明显高于癌旁组织;与正常组织比较,胃癌患者中的血浆miR-214表达明显增高;血浆miR-214表达与患者性别、年龄无关,与疾病分期及生存期密切相关,差异具有统计学意义(P<0.05);Cox回归分析发现疾病分期、miR-214的表达可作为独立的预后因子(P<0.05)。结论循环miR-214表达与胃癌肿瘤分期和生存时间相关,检测循环miR-214可能作为评估胃癌患者临床预后的靶基因。     

非小细胞肺癌患者血浆miR-21水平与化疗疗效的相关性

目的:探讨miRNA-21（miR-21）在非小细胞肺癌（NSCLC）患者血浆中的表达及治疗前后NSCLC患者血浆中miR-21水平与化疗药物疗效的相关性。方法:使用荧光定量PCR法检测并比较15例正常人和26例晚期NSCLC患者血浆中miR-21的表达差异;检测并比较晚期NSCLC患者化疗前后血浆中miR-21的变化水平。结果:NSCLC患者血浆中的miR-21表达水平显著高于正常人（P<0.01）。化疗后患者血浆中miR-21表达水平较化疗前存在差异（P<0.05）。miR-21在（SD+PD）组的表达量高于（CR+PR）组（P<0.05）;而（CR+PR）组血浆miR-21的水平与正常对照组比较,无显著差异（P>0.05）。分析miR-21表达与NSCLC患者临床病理参数相关性,发现miR-21表达与患者临床特征无关。结论:血浆中miR-21的表达水平,对于NSCLC早期诊断及化疗药物治疗后评估患者疗效有较好地评判价值。     

结肠癌转移相关基因1在结肠癌组织中的表达及其临床意义

目的 探讨结肠癌组织中结肠癌转移相关基因1（MACC-1）的表达与结肠癌临床病理特征的关系。方法 采用实时荧光定量PCR和免疫印迹法（Western blotting）检测48例结肠癌组织及其相应癌旁组织中MACC-1 mRNA和蛋白的表达水平。结果 结肠癌组织中MACC-1 mRNA相对表达量为（8.52 ± 2.39）×10^-4,明显高于癌旁组织中的（1.47 ±1.24）×10^-5,差异有统计学意义（P＜0.05）。结肠癌组织中MACC-1蛋白表达的灰度值为7.73±0.03,高于癌旁组织的1.02±0.01（P＜0.05）。结肠癌患者组织中MACC-1 mRNA和蛋白的表达与肿瘤的分化程度、浸润深度、TNM分期显著相关（P＜0.05）,而与年龄、性别无关（P＞0.05）。结论 MACC-1表达的检测对结肠癌的诊断具有一定的临床意义,且MACC-1的表达水平与结肠癌的浸润和转移密切相关,可作为判断结肠癌转移的肿瘤标志物之一。     

结肠癌患者循环miR-630的表达及其临床意义

目的:探讨结肠癌患者外周血中microRNA-630(miR-630)的表达,进一步分析其表达对评估结肠癌进展及预后的价值。方法:使用实时荧光定量PCR（Real time PCR）检测55例结肠癌及21例正常对照者外周血中miR-630的表达,采用统计学方法分析miR-630在结肠癌外周血中的表达及其与肿瘤进展和预后的关系。结果:分析Real time PCR检测结果发现,结肠癌患者外周血中miR-630的表达显著高于正常对照（P<0.05）,外周血中miR-630表达与结肠癌的侵袭、转移和分期显著相关（P<0.05）,单因素和多因素生存分析发现外周血中miR-630的表达上调与结肠癌预后不良显著相关（P<0.05）。结论:结肠癌患者循环miR-630表达显著上调,与结肠癌侵袭和转移密切相关,并可作为结肠癌的独立预后标记分子。     

肺癌患者血清microRNA-21表达临床意义探讨

目的:探讨miRNA-21在肺癌患者血清中的表达及其在肺癌早期诊断的应用价值。方法:收集中山大学孙逸仙纪念医院2011-06-09-2012-10-06收治的90例肺癌患者、40例肺部良性疾病患者和90名健康体检人群作为研究对象,采用Taqman探针实时定量PCR对miRNA-21血清含量进行半定量测定,并依据肺癌患者和两对照组血清miRNA-21相对表达量,利用ROC曲线评价其在肺癌诊断上的灵敏度和特异度。结果:健康组、良性病变组和肺癌组miRNA-21血清平均表达量分别为0.70±0.49、1.38±0.67和1.86±0.85。肺癌患者miRNA-21血清水平显著高于健康对照组和良性肺部疾病组(LSD-t=10.918,P<0.001;LSD-t=3.523,P<0.001),其相对表达量与患者年龄(u=940.000,P=0.626)、性别(u=801.000,P=0.243)、病理类型(χ2=4.109,P=0.128)和临床分期(u=777.000,P=0.085)无关。ROC曲线下面积为0.808(0.750~0.866),当临界值取1.32时,其灵敏度为0.711,特异度为0.823。结论:肺癌患者血清miRNA-21水平显著升高,提示可能是肺癌诊断的潜在肿瘤标志之一。     

结肠癌患者血清中miR-30a、miR-106b的表达及其临床意义

目的:探讨结肠癌患者血清miR-30a、miR-106b的表达及其在结肠癌进展及预测患者预后中的价值.方法:选取2012年06月至2013年02月本院收治的接受结肠癌手术治疗的患者80例为研究对象,20例同期健康人群作为对照组.逆转录PCR法检测外周血血清中miR-30a、miR-106b的表达水平,分析患者血清miR...     

miR-106a和miR-24-1在结肠癌中的表达及意义

 目的
检测结肠癌与癌旁组织miR-106a和miR-24-1的表达差异及其与c-myc的表达是否具有关联性。方法选临床病理诊断明确的结肠癌患者,手术后取癌组织标本提取RNA,RT-PCR检测原癌基因c-myc在结肠癌组织与癌旁组织中的表达。TaqMan荧光定量PCR检测结肠癌与癌旁组织miR-106a和miR-24-1的表达差异。结果c-myc表达阳性的癌组织表达miR-106a要明显高于癌旁组织,其差异具有统计学意义（P<0.05）;c-myc表达阴性的癌组织表达miR-106a要高于癌旁组织（P<0.05）,结肠癌组织与癌旁组织miR-24-1的表达无差异。结论结肠癌组织c-myc阳性组和c-myc阴性组表达miR-106a均高于癌旁组织,miR-106a有可能作为结肠癌的筛查目标之一;结肠癌组织c-myc阳性组和c-myc阴性组表达miR-24-1与癌旁组织无差异,还需更多研究证实其与结肠癌的关系。     

Expression and Clinical Significance of miR-152 and CYFRA21-1 in Ovarian Cancer Tissues

To investigate the expression and clinical significance of miR-152 and CYFRA21-1 in ovarian cancer (OC) tissues. Seventy-four OC patients diagnosed in our hospital from March 2016 to April 2019 (research group, RG) and 30 patients with benign ovarian tumor at the same time (control group, CG) were collected as research objects in this experiment. qRT-PCR and ELISA were used to detect and observe the expression levels of miR-152 in patient tissues and CYFRA21-1 in serum. ROC curves were drawn to analyze the diagnostic value of miR-152 and CYFRA21-1 in OC. The clinicopathological correlation analysis was observed, Pearson was used to examine the correlation between the expression levels of miR- 152 and CYFRA21-1 and carcinoembryonic antigen (CEA), and the 3-year survival rate of patients was observed according to the high and low expression of miR-152 and CYFRA21-1. qRT-PCR and ELISA showed that the miR-152 expression in the RG was dramatically lower than that in the CG, while CYFRA21-1 (μg/L) was remarkably higher than that in the CG (p < 0.05). ROC was drawn based on the miR- 152 and CYFRA21-1 expression levels. The area under miR-152 curve was 0.724 (p < 0.05), and the area under CYFRA21-1 curve was 0.714 (p < 0.05). The expression levels of miR-152 and CYFRA21-1 were relevant to lymph metastasis, differentiation degree and pathological stage of OC patients (p < 0.05). Pearson test analysis identified that miR-152 and CYFRA21-1 were positively correlated with CEA (p < 0.001). The 3-year overall survival rate of miR-152 Low Expression Group (LEG) was 61.54%, that of high expression group (HEG) was 84.85%, that of CYFRA21-1 LEG was 83.75%, and that of HEG was 60.54%. miR-152 shows low expression in the tissues of patients and CYFRA21-1 shows high expression in serum, and both indexes have good diagnostic efficacy. The higher the miR-152 expression is, the higher the survival rate is, while the higher the CYFRA21-1 expression is, the lower the survival rate is.     

miR-140 and miR-196a as Potential Biomarkers in Breast Cancer Patients

Objective: MiR-140 and miR-196a were known to be correlated with cancer diagnosis and prognosis. The current study aimed at the analysis of miR-140 and miR-196a expression patterns and their clinical significance for breast cancer (BC) patients. Methods: Differentially expressed miR-140 and miR-196a were examined via quantitative PCR in 110 cases of BC and their adjacent non-tumor (ANT) tissues. Results: The results indicated that miR-140 and miR-196a, respectively, notably decreased and increased expression in BC samples in comparison with ANT (p<0.001). Reduced miR-140 expression was also related to Lymph node metastasis (LNM, P= 0.023) and stage (P = 0.009). Additionally, Receiver Operating Characteristics (ROC) analysis illustrated that miR-140 had a significant diagnostic accuracy for stage and LNM of BC patients. We also discovered a strong negative correlation between miR-196a expression with histological grade (P = 0.038), LNM (P = 0.012) and stage (P = 0.001). Conclusion: Overall, exploring the miR-140 and miR-196a profiles not only can statistically different among BC and ANT samples, but it is also expected to become potential BC biomarkers.     

微小RNA-133b在胃癌中的表达及意义

目的 研究miR-133b在胃癌细胞、正常胃黏膜上皮永生化细胞、胃癌组织及相应癌旁组织中的表达,探讨miRNA对胃癌发生发展的调控作用。方法 培养7种胃癌细胞株及正常胃黏膜上皮细胞,并收集56例胃癌患者癌组织及相应癌旁组织,提取细胞及组织中总的Small RNA,采用real-timePCR法检测miR-133b在胃癌细胞及组织中的表达,分析miR-133b的表达与细胞分化程度、临床病理特征的关系。结果 miR-133b在胃癌细胞及组织中均表达下调,差异具有统计学意义。miR-133b的低表达与细胞分化程度、TNM分期及有无淋巴结转移显著相关。结论 miR-133b在胃癌细胞及胃癌组织中的表达明显下调,可能作为抑癌基因参与胃癌的发生、发展。     

Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA

Objective： MicroRNA-21 （miR-21） has been shown to be a key regulator of carcinogenesis. There were few reports about the comparison of serum miR-21 with conventional tumor markers. This study aimed to explore the diagnostic value of circulating miR-21 as a tumor marker in breast cancer （BC） and compare it with CA15 3 and carcinoembryonic antigen （CEA）. Methods： Circulating miR-16 and miR-21 were amplified and quantitatively detected by real-time PCR in 89 BC patients and 55 healthy controls. The levels of CA153 and CEA were measured through assays. Then the sensitivity in diagnosis of BC was compared among miR-21, CA153 and CEA. Results： The level of serum miR-21 was significantly higher in BC patients than controls （P〈0.001）. The sensitivity and specificity of miR-21 were 87.6% and 87.3%, respectively, whereas the sensitivities of CEA and CA153 were only 22.47% and 15.73%. Con~lusions： Compared with CEA and CA153, serum miR-21 has a higher sensitivity in diagnosis of BC. Although not correlated with the status of ER, PR and clinical stages, serum miR-21 may be a potential diagnostic indicator for BC, especially for the early stage.     

结肠癌组织和癌旁组织miRNA表达谱研究

目的探讨结肠癌癌组织和癌旁组织中miRNA的表达差异,寻找潜在的结肠癌特异表达谱。方法miRNA表达芯片检测手术切除未发生转移的原位结肠癌组织和癌旁组织标本中miRNA表达水平,并采用Real-time PCR对差异表达的miRNA进行验证。结果miRNA表达芯片分析发现肿瘤细胞中24种miRNA表达下调,27种表达上调。miR-145、miR-143在癌组织中表达显著下调,miR-451在癌组织中表达显著上调,并被Real-time PCR方法进一步证实。结论结肠癌癌组织和癌旁组织中miRNA的表达存在差异,miR-145、miR-143在结肠癌组织中表达下调,miR-451表达上调,结肠癌组织具有特异miRNA表达谱,可作为结肠癌潜在诊断芯片进行开发。     

Ectopic Expression of miR-147 Inhibits Stem Cell Marker and Epithelial–Mesenchymal Transition (EMT)-Related Protein Expression in Colon Cancer Cells

Colon cancer is one of the most common cancers in the world. Epithelial-to-mesenchymal transition (EMT) is a crucial step in tumor progression and is also involved in the acquisition of stem cell-like properties. Some miRNAs have been shown to function as either tumor suppressors or oncogenes in colon cancer. Here we investigated the role of miR-147 in the regulation of the stem cell-like traits of colon cancer cells. We observed that miR-147 was downregulated in several colon cancer cell lines, and overexpressed miR-147 decreased the expression of cancer stem cell (CSC) markers OCT4, SOX2, and NANOG in the colon cancer cell lines HCT116 and SW480. Overexpressed miR-147 inhibited EMT by increasing the expression of epithelial markers E-cadherin and -catenin while decreasing the expression of mesenchymal markers fibronectin and vimentin. Moreover, activation of EMT by TGF- 1 treatment significantly counteracted the inhibitive effect of miR-147 on the expression of CSC markers OCT4, SOX2, and NANOG, supporting the idea that overexpressing miR-147 inhibited stem cell-like traits by suppressing EMT in colon cancer. In addition, we found that overexpressed miR-147 downregulated the expression of -catenin, c-myc, and survivin, which were related to the Wnt/ -catenin pathway. Moreover, treatment of miR-147 mimic-transfected cells with the Wnt/ -catenin pathway activator LiCl attenuated the inhibitive effect of the miR-147 mimic on the EMT and stem cell-like traits of colon cancer cells, indicating that ectopic expression of miR-147 inhibited stem cell-like traits in colon cancer cells by suppressing EMT via the Wnt/ -catenin pathway. In summary, our present study highlighted the crucial role of miR-147 in the inhibition of the stem cell-like traits of colon cancer cells and indicated that miR-147 could be a promising therapeutic target for colon cancer treatment.     

Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer

The present study evaluated the prognostic role of circulating miRNA-618 in patients with metastatic colon cancer (mCC) and whether miR-618 gene rs2682818 single nucleotide polymorphisms (SNP) are associated with colon cancer susceptibility and expression levels of mature miR-618. In total, 104 patients with mCC before starting the chemotherapy were investigated. The expression status of circulating miR-618 in mCC was evaluated by quantitative PCR. TaqMan PCR assay was used for rs2682818 SNP genotyping. miR-618 was overexpressed in serum of mCC patients. Patients with high and intermediate expression of miR-618 had a significantly longer mean overall survival (OS) of 21 months than patients with low expression—16 months. In addition, multivariate Cox regression analysis confirmed the association between high/intermediate levels of miRNA-618 and longer OS, HR = 0.51, 95% CI: 0.30–0.86, p = 0.012. miR-618 rs2682818 SNP significantly decreased the risk of colon cancer susceptibility in both heterozygous codominant (AC vs. CC, OR = 0.39, 95% CI: 0.17–0.88, p = 0.024) and overdominant (AC vs. CC + AA, OR = 0.37, 95% CI: 0.16–0.85, p = 0.018) genetic models. Our data suggest that circulating miRNA-618 could be useful as a prognostic biomarker in mCC. Patients harboring AC rs2682818 genotype have a decreased risk for colon cancer in comparison with patients with CC and AA genotypes.